{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"Number of participants with any concomitant medications prescribed were reported.","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From start of study drug administration up to 22 months","title":"Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed","type":"SECONDARY","unitOfMeasure":"Participants"}